Interview The interview was really smooth, it was long and a real challenge.
United States District Court, E. Attorney s appearing for the Case Charles R. In its complaint, Biovail alleged that Torpharm infringed two of its patents: The patents-in-suit involve extended release forms of Diltiazem, a drug used to treat hypertension and angina.
On November 27,Torpharm moved for summary judgment, arguing that its proposed ANDA product does not Biovail question 1 a "wetting agent" as required by the claims of the patents-in-suit.
Biovail responded to the motion for summary judgment on March 18,alleging that Torpharm's proposed ANDA product does contain a "wetting agent" as defined by Biovail's patent, thereby making Torpharm's proposed ANDA product an infringement of Biovail's patent. On June 9, a hearing was held pursuant to Markman v.
The parties presented the court with a tutorial on their patents and proposed constructions of the term "wetting agent. An extended-release galenical composition of Diltiazem or one or more pharmaceutically-acceptable salts thereof, which comprises beads, said beads consisting essentially of in admixture together: Claim 1 of ' Patent: An extended-release galenical composition of Diltiazem or one or more pharmaceutically-acceptable salts of Diltiazem which comprises beads containing an effective amount of one or more of said Diltiazem salts as the active ingredient, each bead containing one or more of the Diltiazem salts and an effective amount of a wetting agent in admixture with the one Biovail question 1 more Diltiazem salts to maintain the solubility of the Diltiazem in each bead First, the court must determine the scope and meaning of those patent claims disputed by the parties.
Second, the claims as construed by the court are compared limitation by limitation to the features of the allegedly infringing device. The first step, often referred to as "claim construction," typically occurs after a court conducts a "Markman hearing," wherein the parties present arguments for why the court should construe a claim a certain way.
The second step occurs at trial, after the court has issued its decision on how the claims should be construed. The "claim construction inquiry begins and ends in all cases with the actual words of the claim. Next, the court "examine[s] the written description and prosecution history to determine whether the full scope of the definition of a disputed term is covered by the invention or whether that scope has necessarily been limited as a result of the patentee clearly setting forth an inconsistent definition of the disputed term or otherwise disavowing or disclaiming the full scope of the term's meaning.
This is done because, "[a]lthough words in a claim are generally given their ordinary and customary meaning, a patentee may choose to be his own lexicographer and use terms in a manner other than their ordinary meaning, as long as the special definition is clearly stated in the patent specification or file history.
By using this procedure, the court "may avoid improperly importing claim limitations to a single embodiment described in the specification as might occur if the court begins its analysis with an examination of the written description and prosecution history.
The definitions are as follows: Wetting Agents are surface active substances that are used to reduce the contact angle and therefore improve wetting. A Wetting Agent is a surfactant which, when dissolved in water, lowers the advancing contact angle and aids in displacing an air phase at the surface and replacing it with a liquid phase.
Torpharm advocates that I adopt one of these dictionary definitions as the definition of "wetting agent.
Although these dictionary sources provide clear definitions of "wetting agent," "the presumption in favor of a dictionary definition will be overcome where the patentee, acting as his or her own lexicographer, has clearly set forth an explicit definition of the term different from its ordinary meaning.
The "language of the claim defines the boundary of its scope. I therefore turn to the language of the patents to determine whether it provides an explicit definition of "wetting agent. The language thus instructs the reader of the patent to do two things: The reader should not understand the patent's language to mean either that a wetting agent should simply be selected, or, as Biovail would have the court read the language, that one of the items in the Markush group should be selected irregardless of whether it is a wetting agent.
Both steps are necessary.Biovail Corporation, a major Canadian pharmaceutical company listed on the New York Stock Exchange, announces that it will miss its quarterly earnings target by $25 to $45 million, blaming $10 to $15 million of the shortfall on a truck accident involving a shipment that left its facility on the last day of the quarter.
Question 2 Under GAAP the company can recognize if 4 criteria is met, 1) Persuasive evidence of an arrangement – This is the end of the preview.
Sign up to access the rest of the document. Biovail Corporation: Revenue Recognition and FOB Sales Accounting. Introduction: This report presents a detailed quantitative analysis of the truck accident issue as well as assessment of the revenue recognition issues and options available to the management of Biovail Corporation (BC) in this respect.
Biovail interview details: 6 interview questions and 5 interview reviews posted anonymously by Biovail interview candidates.
Bausch Health launches CSR report. We are at the beginning of an exciting new chapter for our company, as we recently changed our name to Bausch Health, an important step in our transformation to an innovative company dedicated to advancing global health. & Williams, Richmond, VA, for Biovail Laboratories International SRL. Amanda M. Kessel, Goodwin Procter LLP, Boston, MA, Annemarie Hassett, Goodwin Procter LLP, New Biovail is the owner of the ' patent, which involves a delayed-release formulation of Currently before me is the question of the proper construction of the claims of the. Financial sustainability is an uphill battle, and the challenge to get to the top can be one of the biggest frustrations we face in our work. Below, we have gathered a list of tips from people who have been through this process.
1 Biovail’s stock was listed on both the Toronto and New York stock exchanges. suggesting that it would make a wonderful interview question for management consultants.9 The majority of Wellbutrin® XL on the truck consisted of bulk tablets in gallon drums Each mg Wellbutrin® XL tablet was estimated to be roughly .
Biovail Corp. (BVF)Q1 Earnings CallMay 6, am ETExecutivesNelson Isabel - VP of IR & Corporate CommunicationsBill Wells - CEOGilbert Godin -.